Markman Advisors
Patent Valuation, Monetization and Investments

Blog

Markman Advisors Patent Blog

by Zachary Silbersher

Posts tagged $BMY
Will Bristol Myers’ patent gamble for Karuna’s KarXT pay off?

Bristol Myers Squibb recently announced a deal to buy Karuna Therapeutics for $14 billion.  Bristol Myers has touted the deal as accelerating the company’s expansion into neuroscience.  Karuna’s lead asset, KarXT, is an antipsychotic that is a combination of two prior drugs, xanomeline and trospium.  Analysts have reported that KarXT could surpass $6 billion in annual sales.  However, that may depend on whether Karuna has protected KarXT with sufficient intellectual property.  Does KarXT have strong enough patent protection to ward off generics for long enough to make Bristol Myers’ gamble pay off?

Read More
Markman AdvisorsBristol-Meyers Squibb, Bristol Myers, Bristol-Myers, BMS, Karuna Therapeutics, Karuna, KarXT, BMY, $BMY, KRTX, $KRTX, patent, Patent Office, Zachary Silbersher, Silbersher, xanomeline, trospium, FDA, fixed dose combination, fixed dose, antipsychotic, schizophreniaComment
If Hatch-Waxman cases are governed by TC Heartland, will that lead to “generic friendly” districts?

Mylan ($MYL) recently prevailed on a motion to dismiss for improper venue in a pending Hatch-Waxman case for the drug Eliquis®.  Mylan successfully argued that Delaware was an improper venue under the recently test for venue in patent cases enunciated by the Supreme Court in TC Heartland.  What are the implications of TC Heartland governing venue in all Hatch-Waxman cases?  Will it lead to “generic friendly” judicial districts?

Read More
Markman AdvisorsMylan, Bristol-Meyers Squibb, MYL, $MYL, $BYL, BYL, $BMY, BMY, TC Heartland, venue, Hatch-Waxman, generic, brand, generic drug, Federal Circuit, Eliquis, Zachary Silbersher, SilbersherComment